Bohana-Kashtan Osnat, Civin Curt I
Department of Oncology, Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA.
Stem Cells. 2004;22(6):908-24. doi: 10.1634/stemcells.22-6-908.
The role of Fas ligand (FasL) in physiologically limiting immune responses and maintaining immune-privileged sites has led to a body of research aiming to confer protection to allogeneic grafts by expressing FasL on the allogeneic tissue or by administrating FasL-transduced donor dendritic cells. In addition, several studies have used FasL to abrogate autoimmune responses. This review presents the results of these studies and discusses the problems associated with FasL usage.
Fas配体（FasL）在生理上限制免疫反应和维持免疫豁免部位中的作用，引发了一系列研究，旨在通过在异体组织上表达FasL或通过给予FasL转导的供体树突状细胞来赋予对异体移植物的保护。此外，一些研究已使用FasL来消除自身免疫反应。本综述展示了这些研究的结果，并讨论了与FasL使用相关的问题。
